Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Verrica Pharmaceuticals Inc. (VRCA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.9500-0.0400 (-1.34%)
At close: 04:00PM EDT
2.9900 +0.04 (+1.36%)
After hours: 04:41PM EDT
Advertisement

Verrica Pharmaceuticals Inc.

44 West Gay Street
Suite 400
West Chester, PA 19380
United States
484 453 3300
https://www.verrica.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees38

Key Executives

NameTitlePayExercisedYear Born
Mr. Ted WhitePres, CEO & Director797.62kN/A1965
Mr. Joe BonaccorsoChief Commercial Officer541.85kN/A1964
Dr. Gary Goldenberg M.D.Chief Medical Officer572.76kN/A1977
Mr. P. Terence KohlerChief Financial OfficerN/AN/AN/A
Mr. Christopher G. HayesChief Legal Officer, Sec., Chief Compliance Officer & Gen. CounselN/AN/A1964
Mr. Eugene ScavolaExec. VP of Technical OperationsN/AN/AN/A
Dr. Bradley J. Catalone MBA, Ph.D.Head of Drug Devel.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Corporate Governance

Verrica Pharmaceuticals Inc.’s ISS Governance QualityScore as of July 31, 2022 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement